所有儿科咨询中约有25％是由于呼吸系统疾病，其中10%用于哮喘。关于患病率，细支气管炎,急性支气管炎,和呼吸道感染是其他主要的儿科呼吸道疾病。与上述疾病相比，儿科急性呼吸窘迫综合征(PARDS)在重症监护病房患者中罕见但致命.根据全球研究，PARDS的死亡率为13.3%至60.7%.在儿科急性肺损伤共识会议（PALICC）之前，PARDS采用成人急性呼吸窘迫综合征(ARDS)治疗指南.PALICC设定了新的标准来识别具有不同治疗和管理方法的PARDS。在某些情况下，类固醇已用于治疗ARDS，尽管它们在治疗儿科患者方面的有效性在科学界存在高度争议。这篇综述探讨了类固醇在治疗PARDS中的使用，强调该领域的当前发展，并对PARDS管理进行了广泛的概述。
Approximately 25% of all pediatric consultations are due to respiratory conditions, 10% of which are for asthma. Regarding prevalence, bronchiolitis, acute bronchitis, and respiratory infections are other leading pediatric respiratory illnesses. Compared to the aforementioned diseases, pediatric acute respiratory distress syndrome (
PARDS) is rare but lethal in the Intensive Care Unit patients. According to global studies, the mortality in
PARDS ranges from 13.3% to 60.7%. Before the Pediatric Acute Lung Injury Consensus Conference (PALICC), adult acute respiratory distress syndrome (ARDS) management guidelines were used for PARDS. The PALICC set new criteria to identify
PARDS with a different treatment and management approach. Steroids have been used to treat ARDS in some cases, although their effectiveness in treating pediatric patients is highly debated in the scientific community. This
review examines steroid use in treating
PARDS, emphasizes current developments in the field, and gives a broad overview of
PARDS management.
PDF(Pubmed)